Valuation Metrics and Recent Changes
As of 4 August 2026, Sun Pharma’s price-to-earnings (P/E) ratio stands at 37.03, a figure that, while still elevated, reflects a moderation from previous levels that classified the stock as very expensive. The price-to-book value (P/BV) ratio is currently 5.60, reinforcing the stock’s expensive valuation status but indicating a slight easing compared to its historical extremes.
Other valuation multiples include an enterprise value to EBIT (EV/EBIT) of 29.58 and an enterprise value to EBITDA (EV/EBITDA) of 24.65. These metrics remain high relative to broader market averages but are consistent with the premium typically accorded to large-cap pharmaceutical companies with strong growth prospects and robust return metrics.
The PEG ratio, which adjusts the P/E for earnings growth, is at 3.65, signalling that the stock is priced with expectations of sustained growth, albeit at a premium. Dividend yield remains modest at 0.82%, reflecting the company’s focus on reinvestment and growth rather than income distribution.
Comparative Peer Analysis
When compared with key peers in the Pharmaceuticals & Biotechnology sector, Sun Pharma’s valuation appears more attractive. Divi’s Laboratories and Torrent Pharmaceuticals are both rated as very expensive, with P/E ratios of 74.14 and 85.41 respectively, and EV/EBITDA multiples of 54.84 and 39.28. Cipla, another large-cap peer, is also classified as expensive but trades at a slightly lower P/E of 33.16 and EV/EBITDA of 20.82.
This relative valuation positioning suggests that while Sun Pharma remains on the higher side of valuation metrics, it offers a more reasonable entry point compared to some of its sector counterparts, particularly those with stretched multiples.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Performance and Returns Context
Sun Pharma’s return profile over various time horizons underscores its resilience and growth potential. Year-to-date (YTD), the stock has delivered a 13.39% return, outperforming the Sensex which is down 7.72% over the same period. Over one year, the stock’s return is 19.70%, again surpassing the Sensex’s negative 2.43% performance.
Longer-term returns are even more compelling, with a three-year gain of 70.93% compared to the Sensex’s 20.54%, and a five-year return of 145.33% versus the benchmark’s 46.11%. However, over a ten-year horizon, the Sensex outperforms Sun Pharma with 183.92% against the company’s 132.59%, reflecting broader market dynamics and sector rotations.
These figures highlight Sun Pharma’s ability to generate substantial shareholder value, particularly in the medium term, supported by its strong operational metrics.
Operational Efficiency and Profitability
Sun Pharma’s return on capital employed (ROCE) stands at an impressive 26.58%, signalling efficient use of capital to generate earnings. Return on equity (ROE) is also robust at 14.92%, indicating healthy profitability relative to shareholder funds. These metrics support the premium valuation, as investors are willing to pay more for companies demonstrating superior capital efficiency and profitability.
Despite the recent day’s decline of 1.98% to ₹1,950 from a previous close of ₹1,989.35, the stock remains near its 52-week high of ₹2,047.55, well above its 52-week low of ₹1,547.25. This price action suggests that the market continues to value Sun Pharma’s growth and quality attributes, even amid short-term volatility.
Valuation Grade Upgrade and Market Implications
On 8 June 2026, Sun Pharma’s Mojo Grade was upgraded from Hold to Buy, reflecting improved valuation appeal and confidence in the company’s fundamentals. The current Mojo Score of 74.0 reinforces this positive stance, categorising the stock as a large-cap buy candidate within the Pharmaceuticals & Biotechnology sector.
This upgrade is significant as it signals a shift in market perception, with valuation parameters moving from very expensive to expensive, thus enhancing the stock’s attractiveness for investors seeking quality exposure in the pharmaceutical space.
Curious about Sun Pharmaceutical Industries Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Conclusion: Assessing Price Attractiveness Amid Sector Dynamics
Sun Pharmaceutical Industries Ltd’s recent valuation adjustment from very expensive to expensive marks a meaningful development for investors. While the stock remains priced at a premium relative to historical averages and many sectors, it offers a comparatively more attractive entry point than several of its pharmaceutical peers.
The company’s strong operational metrics, including high ROCE and ROE, combined with solid medium-term returns, justify a premium valuation. However, the elevated P/E and EV/EBITDA multiples suggest that investors should remain mindful of valuation risks, especially in a sector prone to regulatory and competitive pressures.
Overall, the upgrade to a Buy rating and the improved Mojo Score reflect a growing market confidence in Sun Pharma’s growth trajectory and financial health. For investors seeking exposure to the Pharmaceuticals & Biotechnology sector, Sun Pharma presents a compelling blend of quality, growth, and relative valuation appeal.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
